Sensitive and rapid bioassay for analysis of P-glycoprotein-inhibiting activity of chemosensitizers in patient serum.
M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), P R Twentyman, Rita de Giuli(Kantonsspital St. Gallen)
PubMed
February 1, 1996
Cited by 16
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Clinical multidrug resistance in cancer: A multifactorial problem
|European Journal of Cancer|1996|178